Adrenal Carcinoma

  • Author: Bagi RP Jana, MD; Chief Editor: Jules E Harris, MD, FACP, FRCPC  more...
Updated: Oct 03, 2014

Practice Essentials

Adrenocortical carcinomas (ACs) are uncommon malignancies that can have protean clinical manifestations. A majority of cases are metastatic at the time of diagnosis, with the most common sites of spread being the local periadrenal tissue, lymph nodes, lungs, liver, and bone. AC is relatively rare, however, accounting for just 0.02-0.2% of all cancer-related deaths. Detection of tumors at an early clinical stage is crucial for curative resection. See the image below.

A 68-year-old woman with a large right upper quadr A 68-year-old woman with a large right upper quadrant primary adrenocortical carcinoma with curvilinear calcification. Low-attenuation regions anteriorly are consistent with necrosis.

Signs and symptoms

Physical examination findings in patients with hormonally active AC include the following:

  • Virilization
  • Cushing syndrome
  • Feminization (rare)

Patients with nonfunctional AC typically present with any of the following:

  • Fever
  • Weight loss
  • Abdominal pain and tenderness
  • Back pain
  • Abdominal fullness
  • Symptoms related to metastases

See Clinical Presentation for more detail.


Laboratory studies

These include the following:

  • Serum glucose
  • Serum cortisol
  • Serum adrenal androgen
  • Urine adrenal hormone
  • Urine vanillylmandelic acid (VMA)
  • Urine homovanillic acid (HVA) levels

Imaging studies

Adrenal computed tomography (CT) scanning and magnetic resonance imaging (MRI) are the imaging studies of choice in AC. The typical case is characterized by a large unilateral adrenal mass with irregular edges. The presence of contiguous adenopathy serves as corroborating evidence.

Histologic examination

Some of the macroscopic features of an AC that suggest malignancy include a weight of more than 500 g, the presence of areas of calcification or necrosis, and a grossly lobulated appearance. Histologic findings also include numerous mitoses, scant cytoplasm, and none of the rosettes observed in neuroblastoma.

See Workup for more detail.


When feasible, total resection remains the management modality of choice for the definitive treatment of AC. It also remains the only potentially curative therapeutic modality. While open laparotomy for adrenalectomy represents the standard of care, several reports suggest a role for laparoscopic resection if the adrenal tumor is small and there is no preoperative evidence of metastatic disease.

Medical care in patients with AC, which can be supportive or adjuvant to surgical resection, encompasses the following:

  • Treatment of endocrine excess syndromes
  • Use of mitotane or several multiagent chemotherapy regimens
  • Treatment and prevention of potential complications
  • Strategies for palliative and terminal care issues, including symptom relief and management

See Treatment and Medication for more detail.



Adrenocortical carcinomas (ACs) are uncommon malignancies that can have protean clinical manifestations. A majority of cases are metastatic at the time of diagnosis, with the most common sites of spread being the local periadrenal tissue, lymph nodes, lungs, liver, and bone. ACs are virtually always unilateral, although one report suggests that 2-10% of cases may be bilateral at initial diagnosis; however, this finding has not been replicated (see the image below). (See Etiology, Pathophysiology, and Workup.)

A 68-year-old woman with a large right upper quadr A 68-year-old woman with a large right upper quadrant primary adrenocortical carcinoma with curvilinear calcification. Low-attenuation regions anteriorly are consistent with necrosis.

Adrenocortical masses are common; autopsy studies show that approximately 5-15% of the general adult population may have adrenal incidentalomas, biochemically and clinically asymptomatic adrenal masses found incidentally during unrelated imaging investigations, such as abdominal computed tomography (CT) scanning or magnetic resonance imaging (MRI). Findings from abdominal CT scans suggest that the prevalence is lower, just 1-5%. Ectopic adrenocortical tumors are exceedingly rare. (See Epidemiology and Workup.)

Only a small number of adrenal tumors are functional, and an even smaller number (approximately 1 per 1500) are malignant. The evaluation of adrenal incidentalomas, therefore, focuses on (1) identifying functional masses and treating them appropriately (including surgical removal); (2) identifying adrenal carcinomas early, with the intent of attempting complete surgical extirpation; and (3) reassuring patients whose masses are neither functional nor malignant and arranging for follow-up examinations. (See Presentation, Workup, Treatment, and Medication.)

Classification of adrenal malignancies

Adrenocortical carcinomas

These include the following:

  • Functional
  • Nonfunctional
  • Well differentiated
  • Intermediate
  • Poorly differentiated to anaplastic

Metastatic adrenal tumors

The most common potential primaries include the following:

  • Lung
  • Breast
  • Melanoma
  • Renal cell carcinoma
  • Extra-adrenal lymphoma
  • Leukemias
  • Pancreatic carcinoma
  • Colonic carcinoma
  • Ovarian carcinoma

Adrenomedullary tumors

These include the following:

  • Malignant pheochromocytoma
  • Ganglioneuroblastoma
  • Neuroblastoma
  • Neuroendocrine carcinoma

Stromal malignancies

These include the following:

  • Neurofibrosarcoma
  • Angiosarcoma
  • Liposarcoma
  • Fibrosarcoma
  • Leiomyosarcoma
  • Myxosarcoma
  • Malignant teratoma

Adrenal malignancies in the setting of familial predisposing syndromes

The associated syndromes include the following:

  • Li-Fraumeni syndrome
  • Familial polyposis coli
  • Gardner syndrome
  • Turcot syndrome
  • Cowden syndrome
  • Beckwith-Wiedemann syndrome (possible)
  • Carney complex (possible)
  • Carney triad
  • Multiple endocrine neoplasia type 1 (MEN1)


These include primary adrenal lymphomas, which can be unilateral or bilateral. Adrenal malignancies can also be classified as composite tumors and mixed tumors.

Functional and nonfunctional tumors

Adrenal tumors are classified in several ways. One popular method, which has great clinical relevance, is to subclassify them as functional or nonfunctional, depending on the elaboration of adrenocortical hormones (glucocorticoids, mineralocorticoids, androgens, estrogens; rarely, a host of possible peptides).

Nonfunctional variants of AC were previously reported to be far less common than the functional types; older reports suggested that approximately 50-80% of ACs are functional (patients present mainly with Cushing syndrome). Subsequent reports, however, have suggested that nonfunctional ACs may be more common than previously thought.

Sporadic and syndromic tumors

Another classification method is to subdivide ACs into sporadic and syndromic variants. The syndromic variants occur with multiple cancer predisposition syndromes, including Gardner syndrome, Beckwith-Wiedemann syndrome (associated with hemihypertrophy), multiple endocrine neoplasia type 1, the SBLA syndrome (sarcoma, breast, lung, and adrenal carcinoma and other tumors within several kindreds, which have not been clearly associated with localization to a single gene), and Li-Fraumeni syndrome.

Cellular origin

Adrenal tumors can also be classified based on their cellular origin. Included here are primary ACs, primary adrenal lymphomas, soft-tissue sarcomas of the adrenal, malignant pheochromocytomas, and secondary metastatic adrenal tumors (the common primaries of which are tumors of the breast, kidney, lung, and ovary, as well as melanoma, leukemia, and lymphoma). Only the ACs typically are included in discussions of adrenal cancers, and this monograph will be restricted to those. (See Pathophysiology and Etiology.)

Authorities also report rare composite adrenal tumors, which are different histologic variants of the same embryologic origin (eg, coexisting neuroblastoma and malignant pheochromocytoma), and mixed adrenal tumors (typically, mixtures of pheochromocytomas, spindle cell sarcomas, and adrenocortical carcinomas).



Endocrine syndromes associated with AC include the following:



The exact etiopathogenesis of sporadic AC is unclear, but analysis of syndromic variants of the condition gives some insight. The role of tumor suppressor gene mutations is suggested by their association with Li-Fraumeni syndrome, which is characterized by inactivating germline mutations of the TP53 gene (a vital tumor suppressor gene, or antioncogene) on chromosome 17. This syndrome also is associated with a predisposition to other malignancies, including breast carcinoma, leukemias, osteosarcomas, and soft-tissue sarcomas.

A few reports describe an association between AC and familial adenomatous polyposis, which also is due to an inactivating germline mutation of a tumor suppressor gene (in this case, the adenomatous polyposis coli gene, APC). However, such mutations have not been found in sporadic APC cases.


Suggestions have been made that adrenal hyperplasia predisposes patients to develop AC. A few cases of congenital adrenal hyperplasia are associated with functional adrenocortical adenomas but not carcinoma. A few cases of AC are also associated with primary hyperaldosteronism, in which the adrenal tissue has portions showing adrenocortical hyperplasia. However, definitive proof of a sequence in which hyperplasia leads to adenoma, which then leads to carcinoma—similar to a sequence that produces colonic neoplasms—is lacking.

Carney triad

The association of AC with the Carney triad (GI stromal tumor, pulmonary chondromas, extra-adrenal paraganglioma) is far less defined. Since the Carney triad is so rare, there are very few reported cases.

Genetic mechanisms

Potential mechanisms for adrenocortical tumorigenesis include the following:

  • Activation of various proto-oncogenes: Ras, PKC, C myc, C fos, G proteins, and G protein-coupled receptors (eg, for vasoactive intestinal peptide [VIP], gastric-inhibitory peptide [GIP], luteinizing hormone [LH], catecholamines)
  • Inactivation of tumor suppressor genes (antioncogenes): TP53, TP57, TP16, H19, retinoblastoma gene, APC gene, and various deoxyribonucleic acid (DNA) repair ̶ enzyme genes
  • Inhibition of senescence and/or apoptosis: Mutations involving telomerase and/or BCL-2 genes
  • Changes in adrenocortical tissue-specific factors: Mutations involving the genes for StaR, SF-1 (steroidogenic factor), and Dax-1 transcription factor
  • Aberrant expression of receptors to normal adrenocorticotropic agents and ligands: Adrenocorticotropic hormone, angiotensin 2, catecholamines, and endorphins
  • Ectopic expression of receptors on adrenocortical cells to atypical trophic factors and ligands: Cytokines, growth factors, and neurotransmitters

Among the putative pathogenetic mechanisms that may function in concert with each other are alterations in intercellular communication, paracrine and autocrine effects of various growth factors, cytokines elaborated by the tumor cells, and promiscuous expression of various ligand receptors on cell membranes (causing the cells to be in a state of perpetual hyperstimulation). This is presumed to lead to clonal adrenal cellular hyperplasia, autonomous proliferation, tumor formation, and hormone elaboration.

Some molecular studies of adrenocortical tumor cells show in situ mutations of the TP53 and TP57 genes (both antioncogenes) and increased production of insulinlike growth factor 2 (IGF-2). TP53 gene mutations are the most common mutant genes in human cancer. A potential role for this gene in sporadic AC is suggested by the frequent finding of loss of heterozygosity at the 17p13 locus in cases of sporadic AC. Definite germ cell mutations of the TP53 gene have also been demonstrated in more than 90% of children with AC from southern Brazil, which has the highest prevalence of sporadic AC in the world. Amplification of steroidogenic factor-1 expression has also been described in this population.

Another genetic locus of interest is the 11p chromosomal region that may also harbor a tumor suppressor gene and has been implicated in linkage studies in subjects with the Beckwith-Wiedemann syndrome. Loss of heterozygosity at band 11p15 and overexpression of IGF-2, whose gene is carried on this genetic locus, have been described in cases of sporadic AC.

Other studies demonstrate that some of AC cells express menin (the aberrant gene product in patients with multiple endocrine neoplasia type I [MEN1]); in other cases, the hybrid gene is associated with glucocorticoid-responsive aldosteronism (GRA).

Several reports suggest that, while benign adrenal tumors retain expression of the type 2 MHC antigens, these are lost in adrenocortical carcinoma cells. Furthermore, while adrenal adenomas can be monoclonal (43%), polyclonal (28%), or mixed (28%), virtually all ACs are monoclonal.

The fact that the normal adrenal cortex has multiple areas of adrenomedullary cells (often forming large cell nests) and that adrenocortical cells also are scattered in the adrenal medulla suggests a close interaction between the two groups of cells, despite their distinct phylogenetic and embryonic origins. The relevance of the paracrine interactions of these cells in the etiopathogenesis of AC and adrenal tumors as a whole is still being actively investigated.



AC tumors are uncommon, having an incidence of approximately 0.6-1.67 cases per million persons per year. In southern Brazil, however, the incidence of adrenal tumors is 10-15 times that of the general population, a difference that has been associated with a mutation in the P53 gene.

Sex- and age-related demographics

The female-to-male ratio for ACs is approximately 2.5-3:1. The accumulation of data, especially in international registries, revealed the incidence of adrenal tumors to be higher in female individuals than had previously been thought, particularly in those aged 0-3 years and those over 13 years. Nonfunctional ACs are distributed equally between the sexes.

AC occurs in 2 major peaks: in the first decade of life and again in the fourth to fifth decades. While, functional tumors are more common in children, however, nonfunctional tumors are more common in adults.

Based on data from the International Pediatric Adrenocortical Tumor Registry, the median age at which children develop adrenal carcinomas is 3.2 years; 60% are younger than four years, and 14% are older than 13 years.[1]



AC is relatively rare, accounting for just 0.02-0.2% of all cancer-related deaths. The most important predictive clinical parameters of prognosis are as follows:

  • Disease stage at diagnosis
  • Completeness of resection at surgery
  • Presence or absence of metastasis at the time of diagnosis

Follow-up data from large centers, such as the MD Anderson Cancer Center and the Memorial Sloan-Kettering Cancer Center, suggest a temporal improvement in clinical survival of patients with AC since the late 1980s and early 1990s.

Male patients tend to be older and have a worse overall prognosis than do female patients. Female patients are more likely than male patients to have an associated endocrine syndrome. Although still somewhat controversial, some suggest that children with AC have a better prognosis than do adults; favorable clinical outcome has been reported in 70% or more of pediatric cases.[2]

Detection of tumors at an early clinical stage is crucial for curative resection; total resection offers the only prospect for cure. The estimated overall five-year survival rate for patients with AC is approximately 20-35%. For cases in which total surgical resection is achieved, this rate is estimated to be approximately 32-47%, while in cases in which total surgical extirpation has not been possible, the five-year survival rate is estimated to be 10-30%.[3]

Even after apparently complete surgical resection, however, local or distant relapse occurs in nearly 80% of cases. Documented cases exist of AC recurrence more than 10 years after presumed curative surgery. Recurrent or relapsing AC is usually a bad omen. Although symptoms of hormonal excess can often be medically managed in this setting, cure is virtually unknown.

The presence of distant metastasis generally is another sign of an especially poor outcome. Estimates suggest that as many as 50% of such patients are dead within 12 months of detecting metastatic deposits, regardless of treatment. Indeed, patients with functional AC may have a better prognosis because they present earlier, unlike patients with nonfunctional variants, who invariably present when the tumors are very large or are associated with distant metastasis.

Estrogen receptor (ER)–negative status also confers a worse prognosis in AC. In a study of 17 patients, Shen et al found that one- and five-year survival rates were 86% and 60%, respectively, for patients with ER-positive tumors, versus 38% and 0% for those with ER-negative tumors.[4]

The prognosis for cases of AC occurring in pregnancy is also grim; however, the fetal prognosis in these cases remains excellent.

Patients who show no response to mitotane or who relapse are probably best served by referral to a major cancer center, where they can be enrolled in one of several ongoing combination chemotherapeutic/radiation and/or surgical resection protocols. AC is too uncommon for most tertiary hospitals to have enough expertise to manage these patients adequately.



Potential complications associated with AC can be subclassified as follows:

  • Local tumor invasion: Including the potential for tumor thrombus formation, which can embolize similar to renal cell carcinoma
  • Hormone excess syndromes (eg, Cushing syndrome, hyperaldosteronism, hirsutism, virilization, hypertension)
  • Paraneoplastic syndromes (eg, cachexia)
  • Local pain in patients with bone metastases

While AC accounts for only approximately 5-10% of cases of Cushing syndrome, approximately 40% of patients with both Cushing syndrome and an adrenal mass also have a malignant tumor. Virtually all feminizing adrenal tumors in men are malignant.

Contributor Information and Disclosures

Bagi RP Jana, MD Associate Professor of Medicine (Genitourinary Oncology), Division of Hematology and Oncology, University of Texas Medical Branch

Bagi RP Jana, MD is a member of the following medical societies: American Cancer Society, American Medical Association, SWOG, American Society of Clinical Oncology

Disclosure: Nothing to disclose.


Kush Sachdeva, MD Southern Oncology and Hematology Associates, South Jersey Healthcare, Fox Chase Cancer Center Partner

Disclosure: Nothing to disclose.

Chief Editor

Jules E Harris, MD, FACP, FRCPC Clinical Professor of Medicine, Section of Hematology/Oncology, University of Arizona College of Medicine, Arizona Cancer Center

Jules E Harris, MD, FACP, FRCPC is a member of the following medical societies: American Association for the Advancement of Science, American Society of Hematology, Central Society for Clinical and Translational Research, American Society of Clinical Oncology

Disclosure: Nothing to disclose.


Robert J Arceci, MD, PhD King Fahd Professor of Pediatric Oncology, Professor of Pediatrics, Oncology and the Cellular and Molecular Medicine Graduate Program, Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine

Robert J Arceci, MD, PhD is a member of the following medical societies: American Association for Cancer Research, American Association for the Advancement of Science, American Pediatric Society, American Society of Hematology, and American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.

Timothy P Cripe, MD, PhD Professor of Pediatrics, Division of Hematology/Oncology, Cincinnati Children's Hospital Medical Center; Clinical Director, Musculoskeletal Tumor Program, Co-Medical Director, Office for Clinical and Translational Research, Cincinnati Children's Hospital Medical Center; Director of Pilot and Collaborative Clinical and Translational Studies Core, Center for Clinical and Translational Science and Training, University of Cincinnati College of Medicine

Timothy P Cripe, MD, PhD is a member of the following medical societies: American Association for the Advancement of Science, American Pediatric Society, American Society of Hematology, American Society of Pediatric Hematology/Oncology, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Antonio Tito Fojo, MD Senior Clinical Investigator, Medicine Branch, Division of Cancer Treatment, National Cancer Institute, National Institutes of Health

Disclosure: Nothing to disclose.

Samuel Gross, MD Professor Emeritus, Department of Pediatrics, University of Florida; Clinical Professor, Department of Pediatrics, University of North Carolina; Adjunct Professor, Department of Pediatrics, Duke University

Samuel Gross, MD is a member of the following medical societies: American Association for Cancer Research, American Society for Blood and Marrow Transplantation, American Society of Clinical Oncology, American Society of Hematology, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Gabriel I Uwaifo, MD Associate Professor, Section of Endocrinology, Diabetes and Metabolism, Louisiana State University School of Medicine in New Orleans; Adjunct Professor, Joint Program on Diabetes, Endocrinology and Metabolism, Pennington Biomedical Research Center in Baton Rouge

Gabriel I Uwaifo, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Physicians-American Society of Internal Medicine, American Diabetes Association, American Medical Association, American Society of Hypertension, and The Endocrine Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Lawrence C Wolfe, MD Senior Associate in Pediatric Hematology/Oncology, Schneider Children's Hospital

Lawrence C Wolfe, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Association of Blood Banks, American Society of Hematology, Children's Oncology Group, and Eastern Society for Pediatric Research

Disclosure: Nothing to disclose.

  1. Michalkiewicz E, Sandrini R, Figueiredo B, Miranda EC, Caran E, Oliveira-Filho AG, et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol. 2004 Mar 1. 22(5):838-45. [Medline].

  2. Dehner LP, Hill DA. Adrenal cortical neoplasms in children: why so many carcinomas and yet so many survivors?. Pediatr Dev Pathol. 2009 Jul-Aug. 12(4):284-91. [Medline].

  3. Tritos NA, Cushing GW, Heatley G, Libertino JA. Clinical features and prognostic factors associated with adrenocortical carcinoma: Lahey Clinic Medical Center experience. Am Surg. 2000 Jan. 66(1):73-9. [Medline].

  4. Shen XC, Gu CX, Qiu YQ, Du CJ, Fu YB, Wu JJ. Estrogen receptor expression in adrenocortical carcinoma. J Zhejiang Univ Sci B. 2009 Jan. 10(1):1-6. [Medline]. [Full Text].

  5. Chen QL, Su Z, Li YH, Ma HM, Chen HS, Du ML. Clinical characteristics of adrenocortical tumors in children. J Pediatr Endocrinol Metab. 2011. 24(7-8):535-41. [Medline].

  6. Shah NS, Lila A. Childhood Cushing disease: a challenge in diagnosis and management. Horm Res Paediatr. 2011. 76 Suppl 1:65-70. [Medline].

  7. Angeli A, Osella G, Alì A, Terzolo M. Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group. Horm Res. 1997. 47(4-6):279-83. [Medline].

  8. Hamrahian AH, Ioachimescu AG, Remer EM, Motta-Ramirez G, Bogabathina H, Levin HS, et al. Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. J Clin Endocrinol Metab. 2005 Feb. 90(2):871-7. [Medline].

  9. Williams AR, Hammer GD, Else T. Transcutaneous biopsy of adrenocortical carcinoma is rarely helpful in diagnosis, potentially harmful, but does not affect patient outcome. Eur J Endocrinol. 2014 Jun. 170(6):829-35. [Medline].

  10. Villelli NW, Jayanti MK, Zynger DL. Use and Usefulness of Adrenal Core Biopsies Without FNA or On-site Evaluation of Adequacy: A Study of 204 Cases for a 12-Year Period. Am J Clin Pathol. 2012 Jan. 137(1):124-31. [Medline].

  11. Lau SK, Weiss LM. The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum Pathol. 2009 Jun. 40(6):757-68. [Medline].

  12. Soon PS, Gill AJ, Benn DE, Clarkson A, Robinson BG, McDonald KL, et al. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocr Relat Cancer. 2009 Jun. 16(2):573-83. [Medline].

  13. Duregon E, Molinaro L, Volante M, Ventura L, Righi L, Bolla S, et al. Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma. Mod Pathol. 2014 Jan 17. [Medline].

  14. International Union Against Cancer. TNM Classification of MalignantTumours - 7th edition. Available at Accessed: December 1, 2009.

  15. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009 Jan 15. 115(2):243-50. [Medline].

  16. Baudin E, Leboulleux S, Al Ghuzlan A, Chougnet C, Young J, Deandreis D, et al. Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011?. Horm Cancer. 2011 Dec. 2(6):363-71. [Medline].

  17. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007 Jun 7. 356(23):2372-80. [Medline].

  18. Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT, et al. Recurrence of Adrenal Cortical Carcinoma Following Resection: Surgery Alone Can Achieve Results Equal to Surgery Plus Mitotane. Ann Surg Oncol. 2009 Oct 23. [Medline].

  19. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012 Jun 7. 366(23):2189-97. [Medline].

  20. Ronchi CL, Sbiera S, Kraus L, Wortmann S, Johanssen S, Adam P, et al. Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocr Relat Cancer. 2009 Sep. 16(3):907-18. [Medline].

  21. Polat B, Fassnacht M, Pfreundner L, Guckenberger M, Bratengeier K, Johanssen S, et al. Radiotherapy in adrenocortical carcinoma. Cancer. 2009 Jul 1. 115(13):2816-23. [Medline].

  22. Kazaryan AM, Marangos IP, Rosseland AR, Røsok BI, Villanger O, Pinjo E, et al. Laparoscopic adrenalectomy: Norwegian single-center experience of 242 procedures. J Laparoendosc Adv Surg Tech A. 2009 Apr. 19(2):181-9. [Medline].

  23. Zografos GN, Vasiliadis G, Farfaras AN, Aggeli C, Digalakis M. Laparoscopic surgery for malignant adrenal tumors. JSLS. 2009 Apr-Jun. 13(2):196-202. [Medline].

  24. Kulis T, Knezevic N, Pekez M, Kastelan D, Grkovic M, Kastelan Z. Laparoscopic Adrenalectomy: Lessons Learned from 306 Cases. J Laparoendosc Adv Surg Tech A. 2011 Dec 13. [Medline].

  25. Agha A, Iesalnieks I, Hornung M, Phillip W, Schreyer A, Jung M, et al. Laparoscopic trans- and retroperitoneal adrenal surgery for large tumors. J Minim Access Surg. 2014 Apr. 10(2):57-61. [Medline]. [Full Text].

  26. Datrice NM, Langan RC, Ripley RT, Kemp CD, Steinberg SM, Wood BJ, et al. Operative management for recurrent and metastatic adrenocortical carcinoma. J Surg Oncol. 2011 Dec 20. [Medline].

  27. Hermsen IG, Gelderblom H, Kievit J, Romijn JA, Haak HR. Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma. Eur J Endocrinol. 2008 Jun. 158(6):911-9. [Medline].

  28. Kemp CD, Ripley RT, Mathur A, et al. Pulmonary resection for metastatic adrenocortical carcinoma: the National Cancer Institute experience. Ann Thorac Surg. 2011 Oct. 92(4):1195-200. [Medline].

  29. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol. 1999 Dec. 6(8):719-26. [Medline].

  30. Hah JO. Intensive chemotherapy with autologous PBSCT for advanced adrenocortical carcinoma in a child. J Pediatr Hematol Oncol. 2008 Apr. 30(4):332-4. [Medline].

A 68-year-old woman with a large right upper quadrant primary adrenocortical carcinoma with curvilinear calcification. Low-attenuation regions anteriorly are consistent with necrosis.
Medscape Consult
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.